Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05117632 · ClinicalTrials.gov registry record · Phase 2
ALTO-100 in MDD and/or PTSD
A Phase 2 study of Major Depressive Disorder and Post Traumatic Stress Disorder, sponsored by Alto Neuroscience.
- Completed
- Registry status
- Phase 2
- Development phase
- 245
- Enrollment target
- 20
- Study locations
NCT05117632: Completed Phase 2 study of Major Depressive Disorder and Post Traumatic Stress Disorder, sponsored by Alto Neuroscience.
NCT05117632 is a Phase 2 study of Major Depressive Disorder and Post Traumatic Stress Disorder that has completed, run by Alto Neuroscience. The registered enrollment target is 245 participants, below the 376-participant average among 282 other Major Depressive Disorder trials with a reported enrollment target (35% lower). The trial reports 20 study locations across 13 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT05117632, a Phase 2 study of Major Depressive Disorder and Post Traumatic Stress Disorder, has completed, sponsored by Alto Neuroscience.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 245 participants
- Enrollment target
- 20
- Study locations
Study Summary
The goal of this study is to collect biologically based data for defining predictors and correlates of the effects of ALTO-100.
Primary Outcome
The Montgomery-Åsberg Depression Rating Scale (MADRS) measures the severity of depression where smaller scores indicate less depression and higher scores suggest more severe depression. Possible scores for this 10 item version range from 0 to 60. The change from baseline to the end of the study is the primary outcome.
Conditions Studied
Interventions
- DRUG ALTO-100 PO tablet
Study Locations (20)
California
- Site 141 - Costa Mesa
- Site 118 - Fresno
- Site 116 - Martinez
- Site 116 - Mather
Texas
- Site 147 - Fort Worth
- Site 148 - Fort Worth
- Site 120 - Houston
- Site 113 - Houston
Florida
- Site 150 - Boca Raton
- Site 112 - Doral
Arizona
- Site 136 - Tempe
Arkansas
- Site 139 - Little Rock
Illinois
- Site 155 - Elgin
Indiana
- Site 137 - Noblesville
Maryland
- Site 151 - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 245 participants |
| Start Date | 2021-12-20 |
| Est. Completion | 2022-12-09 |
| Phase | Phase 2 |
What the finished NCT05117632 record still lists
NCT05117632 is an interventional study that assigns participants to a tested intervention. The registered 245 participants enrollment target is mid-sized for trials with a published cap, below the 376-participant average among 282 other Major Depressive Disorder trials with a reported enrollment target (35% lower).
The record links to 2 conditions, with Major Depressive Disorder appearing as the primary indexed condition, and to 1 intervention - of which ALTO-100 PO tablet is the first listed.
NCT05117632 names 20 study sites across 13 states, led by California, Texas, Florida.
Frequently Asked Questions
What is clinical trial NCT05117632 about?
NCT05117632 is a clinical study titled "ALTO-100 in MDD and/or PTSD". The goal of this study is to collect biologically based data for defining predictors and correlates of the effects of ALTO-100.
What is the current status of trial NCT05117632?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 245 participants. The study started on 2021-12-20. Estimated completion is 2022-12-09.
What conditions does trial NCT05117632 study?
This clinical trial studies the following conditions: Major Depressive Disorder, Post Traumatic Stress Disorder.
What interventions are being tested in trial NCT05117632?
The interventions under investigation include: ALTO-100 PO tablet (DRUG).
Who is sponsoring clinical trial NCT05117632?
This trial is sponsored by Alto Neuroscience, which has 10 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05117632 being conducted?
This trial has 20 study locations across Arizona, Arkansas, California, Florida, Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Major Depressive Disorder
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT05117632's enrollment target sits among peer trials
245 62nd of 282 higher than 221 of 282 other Major Depressive Disorder trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Major Depressive Disorder trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
A Phase 2 Study of Zelquistinel or Placebo for the Reduction of Symptoms of Major Depressive Disorder
RECRUITING · Phase 2
-
A Study to Assess Change in Disease Activity and Adverse Events of Oral Icalcaprant in Adult Participants With Major Depressive Disorder
RECRUITING · Phase 2
-
Study of ALTO-300 in MDD
RECRUITING · Phase 2
-
Regulation of Affect and Physiology in Depression
RECRUITING · Phase 2
-
Sodium-Glucose Cotransporter-2 Inhibitor (SGLT2) in Major Depressive Disorder (MDD)
RECRUITING · Phase 2
-
A Study of the Efficacy and Safety of SP-624 in the Treatment of Adults With Major Depressive Disorder
RECRUITING · Phase 2
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03645928 · 245 participants · Phase 2
Study of Autologous Tumor Infiltrating Lymphocytes in Patients With Solid Tumors
- NCT04718168 · 245 participants · NA
GORE® ENFORM Biomaterial Product Study
- NCT05145127 · 245 participants · Phase 3
Open-Label Extension Study of Marstacimab in Hemophilia Participants With or Without Inhibitors
- NCT05446259 · 245 participants
Degenerative Cervical Myelopathy Repository
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI